Chaurasia S, Patel RR, Vure P, Mishra B. Oral naringenin nanocarriers: Fabrication, optimization, pharmacokinetic and chemotherapeutic efficacy assessments.
Nanomedicine (Lond) 2017;
12:1243-1260. [PMID:
28593828 DOI:
10.2217/nnm-2016-0436]
[Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
AIM
To enhance oral bioavailability and chemotherapeutic efficacy of naringenin (NG) by fabricating the NG-encapsulated Soluthin-maltodextrin-based nanocarrier (NC) system.
MATERIALS & METHODS
NG-encapsulated nanocarriers (NG/NCs) were developed, and in vitro physicochemically characterized. Furthermore, Wistar rats were used to evaluate the pharmacokinetic profile. Furthermore, in vitro and in vivo colorectal cancer efficacy was evaluated in BALB/c mice-bearing colon-26 cells.
RESULTS
The NG/NCs demonstrated favorable mean particle size (176 ± 2.35 nm) and percent entrapment efficiency (70.83 ± 4.55%), respectively. The oral bioavailability was found to be approximately 116-fold higher and in vitro cytotoxicity exhibited approximately 21-fold reduction as compared with pure NG. Moreover, optimized NG/NCs demonstrated significant tumor suppression compared with pure NG in vivo.
CONCLUSION
The NG/NCs would be an efficient formulation for enhancing oral bioavailability and chemotherapeutic efficacy of NG.
Collapse